Open AccessTime to untreatable progression is an appropriate surrogate endpoint for overall survival in patients with hepatocellular carcinoma after transarterial chemoembolization
Author(s) -
Hongyu Wang,
Bin Li,
Yu Wang,
Jiang Zhang,
Yanqin Wu,
Wenzhe Fan,
Jiaping Li
Publication year - 2020
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_898_19
Subject(s) - hepatocellular carcinoma , medicine , sorafenib , hazard ratio , clinical endpoint , surrogate endpoint , stage (stratigraphy) , confidence interval , proportional hazards model , oncology , liver cancer , progression free survival , gastroenterology , tumor progression , overall survival , cancer , clinical trial , biology , paleontology
The aim of the study was to determine whether the time to progression (TTP) or time to untreatable progression (TTUP) is an appropriate surrogate endpoint for overall survival (OS) in patients with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE).